ClinicalTrials.gg
CompletedNCT05229484Updated Apr 15, 2022

Effects of an Integrated Multimodal Lifestyle Intervention for Management of Violence in Schizophrenia

An interventional study of an integrated multimodal lifestyle intervention (MLifeI) in Schizophrenia, sponsored by I-Shou University. Completed at 1 site in Taiwan. Open to participants aged 20 Years to 65 Years. Per ClinicalTrials.gov, last updated 2022-04-15.

Sponsored by I-Shou University · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Registered 5 years 4 months after the study started (first participant enrolled Aug 2016, registered Jan 2022).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
62
Allocation
Randomized
Ages
20 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 181 studies in Schizophrenia with a site in Taiwan — 23 open to participants now, 26 under way, none of them phase 3. Schizophrenia · Taiwan.

Enrollment
100th of 153
62 · median 85
Started
2016
with 6 others
No phase
56 of 181
9 open now
Registered
144th of 181
by date

Among the 181 studies in Schizophrenia with a site in Taiwan, this one is the 100th largest by enrollment of the 153 interventional ones that give a count, is one of 7 that started in 2016, is one of 56 with no phase, and was the 144th registered.

Schizophrenia

3,574 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

23 of the 181 studies in Schizophrenia with a site in Taiwan are open now. Recruiting first, the newest first:

18 more — sign in →

All 23 open studies →

A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 20 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 181 studies in Schizophrenia with a site in Taiwan, or all of them as a file.
02

Study summary

Total cholesterol levels and other lipids are associated with violence in psychiatric patients. There is a paucity of studies on preventive interventions. In this study, an integrated multimodal lifestyle intervention (MLifeI) for management of repetitive violence in schizophrenia is proposed. A controlled clinical trial was carried out to evaluate the effects of MLifeI on management of repetitive violence through regulation of serum lipids, TC in particular, to the recommended levels in schizophrenia. The investigators examined whether the MLifeI could: 1. regulate or balance lipid profiles; 2. reduce violence risk; 3. improve impulsivity; and 4. improve general cognitive functioning.

Read the detailed description

Total cholesterol levels and other lipids are associated with violence in psychiatric patients. There is a paucity of studies on preventive interventions. In this study, an integrated multimodal lifestyle intervention (MLifeI) for management of repetitive violence in schizophrenia is proposed. A controlled clinical trial was carried out to evaluate the effects of MLifeI on management of repetitive violence through regulation of serum lipids, TC in particular, to the recommended levels in schizophrenia. The investigators examined whether the MLifeI could: 1. regulate or balance lipid profiles; 2. reduce violence risk; 3. improve impulsivity; and 4. improve general cognitive functioning. The multimodal lifestyle intervention included psychoeducation, lifestyle modification and health promotion and exercise. Outcome measures comprised lipid profiles, body mass index and violence-related parameters.

03

Conditions studied

  • Schizophrenia

Browse trials for

Keywords

  • Lifestyle Intervention
  • Management of Violence
  • Lipid Profile
04

Who can participate

Ages eligible
20 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical diagnosis of schizophrenia for more than 2 years
  • Psychiatrically hospitalized
  • Repetitive violence within one year
  • Ambulatory
  • Having basic literacy
  • More than 20 years old
  • Less than 65 years old

Exclusion criteria

Exclusion Criteria:

  • Clinical psychiatric diagnosis other than schizophrenia
  • Physical co-morbidity or life-threatening illnesses that may impact on lipid homeostasis
  • dietary restrictions for physical condition
  • pregnancy
  • reported disabilities
  • impairments or health illness/problems that significantly limited their ability to perform the intervention such as severe arthritis, uncorrected visual or hearing impairments, developmental disability, or signs of intellectual disability.
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
62 participants (actual)

Study arms

  • Experimental
    Intervention Group: an integrated multimodal lifestyle intervention (MLifeI)

    The MLifeI program focused on the roles of health responsibility, review of lipid profile, complications of imbalanced lipid profile, lipid management and nutritional education.

    Other: an integrated multimodal lifestyle intervention (MLifeI)

  • No intervention
    Control group

    The control group is the Treatment as Usual (TAU).

Interventions

  • Otheran integrated multimodal lifestyle intervention (MLifeI)

    The MLifeI program focused on the roles of health responsibility, review of lipid profile, complications of imbalanced lipid profile, lipid management and nutritional education.

06

What researchers measure

Primary outcomes

  1. Weight in kilograms

    Clinical Assessment: weight.

    Time frame: Change of weight from baseline and 6 months (3-month follow-up)

  2. Height in meters

    Clinical Assessment: height.

    Time frame: Change of weight from baseline and 6 months (3-month follow-up)

  3. Body Mass Index (BMI)

    Clinical Assessment: Body Mass Index; Weight and height will be combined to report BMI in kg/m\^2. The World Health Organisation defines an adult who has a BMI between 25 and 29.9 as overweight - an adult who has a BMI of 30 or higher is considered obese - a BMI below 18.5 is considered underweight, and between 18.5 to 24.9 a healthy weight.

    Time frame: Change of weight from baseline and 6 months (3-month follow-up)

  4. Routine test in the ward of total cholesterol, triglyceride, low-density lipoprotein and high-density lipoprotein (Change is being assessed, mg/dL)

    Lipid profiles. Assessment of serum metabolites.

    Time frame: Change of violence risk from baseline (T1) and 6 months (T3, 3-month follow-up)

  5. Violence Risk Screening (Change is being assessed)

    Questionnaires of violence. A higher score indicates a higher violence risk.

    Time frame: Change of violence risk from baseline (T1), 3 months (T2, end of treatment), and 6 months (T3, 3-month follow-up)

  6. Attribution Questionnaire (Change is being assessed)

    Questionnaires of violence attributions. The Attribution Questionnair was applied to measure the participant's internal/external attributions about the causality and likelihood of violence and responsibility for changing the behavior. The measure was rated on a continuum scale from 1 (e.g., not at all likely; not at all able, etc.) to 7 (e.g., totally due to me; totally likely; totally able, etc.).

    Time frame: Change of violence risk from baseline (T1), 3 months (T2, end of treatment), and 6 months (T3, 3-month follow-up)

  7. Modified Overt Aggression Scale (Change is being assessed)

    Questionnaires of aggression frequency.

    Time frame: Change of violence risk from baseline (T1), 3 months (T2, end of treatment), and 6 months (T3, 3-month follow-up)

  8. Buss-Perry Aggression Questionnaire (Change is being assessed)

    Questionnaires of violence/aggression. The higher the score is, the higher the participant has the violent behavior.

    Time frame: Change of violence risk from baseline (T1), 3 months (T2, end of treatment), and 6 months (T3, 3-month follow-up)

  9. Barratt Impulsiveness Scale (Change is being assessed)

    Questionnaires of impulsivity. The score ranged from 1 (rarely/never) to 4 (almost always/always). The higher the scores indicates the greater the impulsivity.

    Time frame: Change of violence risk from baseline (T1), 3 months (T2, end of treatment), and 6 months (T3, 3-month follow-up)

  10. Mini-Mental State Examination (Change is being assessed)

    Questionnaires of cognitive functioning. The MMSE ranged from 0 to 30, where higher scores indicate better cognitive functioning.

    Time frame: Change of violence risk from baseline (T1), 3 months (T2, end of treatment), and 6 months (T3, 3-month follow-up)

07

Study locations

1 site
  • I-Shou University
    Kaohsiung City, Taiwan
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2016 to primary completion in Aug 2018, 23 months.

Of 763 non-industry interventional studies with no phase under Schizophrenia, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 56. This study's 23 months is below that.

Counting every sponsor, half of 776 studies reached it within 32 months; a quarter within 16 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 6, 2022
First posted
Feb 8, 2022
StartActual
Aug 15, 2016
Primary completionActual
Aug 14, 2018
CompletionActual
Aug 14, 2018
Last update
Apr 15, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 15, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05229484
Lead sponsor
I-Shou University
Responsible party
Mei-Chi Hsu (Professor, I-Shou University) — Principal investigator
First posted
Feb 8, 2022
Start date
Aug 15, 2016
Primary completion
Aug 14, 2018
Completion
Aug 14, 2018
Last update
Apr 15, 2022

Study contacts

Mei-Chi Hsu, Ph.D
principal investigator · I-Shou University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion